Table 1.

Tumor features associated with cytoplasmic FGF2 expression assessed by IHC in an invasive breast cancer tissue microarray

FGF2 positiveFGF2 negativeP
n24175
Pathology
 IDC241250.013
 ILC044
 Other06
Median tumor size (mm)20.5201a
Histologic grade
 10230.0005b
 2156
 32391
Vascular invasion75% (18/24)69% (120/175)0.64
Axillary node positive63% (16/24)67% (117/175)1
ER positive21% (5/24)86% (151/175)<0.0001
PR positive25% (6/24)77% (135/175)<0.0001
HER2 positive13% (3/24)13% (23/175)1
EGFR42% (10/24)5% (8/175)<0.0001
CK5/658% (14/24)5% (8/175)<0.0001
CK1446% (11/24)4% (7/175)<0.0001
Any basal marker79% (19/24)9% (15/175)<0.0001
Tumor subtype
 Luminal5133<0.0001b
 HER2323
 Core basal-like1610
 TN nonbasal09

Abbbreviations: IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; CK5/6, cytokeratin 5/6; CK14, cytokeratin 14, any basal-marker (positive for any of EGFR, CK5/6 or CK14).

NOTE: Statistical analysis was with Fisher's exact test, unless indicated. Tumor subtype as defined by Nielsen and colleagues (ref. 28; HER2–HER2 amplified, Luminal–HER2 negative/ER positive, core basal-like–TN expressing CK5/6 or EGFR, TN nonbasal–TN with no expression of CK5/6 and EGFR).

  • aMann–Whitney U Test or

  • bχ2 test.